Apimeds Pharmaceuticals US, Inc. (APUS) stock
APUSNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.89−0.06 (-3.08%)
Close on Nov 18, 2026Market cap $2.85MP/E –Yield –
Apimeds Pharmaceuticals US free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Apimeds Pharmaceuticals US's free cash flow for the twelve months ending Sep 30, 2026 was -$11.80M. For fiscal 2025 it was -$8.98M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$8.98M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$218.62K | – |
| Q2 FY2026 | Jun 30, 2026 | -$5.67M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.08M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.84M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.75M | – |
See a number that looks wrong?